Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to sharpen kidney recovery checks after AKI

NCT ID NCT07569588

Knowledge-focused Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at better ways to check kidney function after acute kidney injury (AKI). Researchers will compare two blood tests (creatinine and cystatin C) to see which is more reliable. They will also interview patients about their recovery experiences and hold workshops to develop recommendations for improving follow-up care. The study involves 100 adults who had moderate to severe AKI during a hospital stay.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could lead to better, more reliable ways to assess kidney function after AKI and improve follow-up care for patients.
What could go wrong
This is an early-stage observational study with only 100 participants, so findings may not apply to all AKI patients. It aims to gather knowledge, not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Observational study workstream: secondary care nephrology clinics Qualitative interview workstream: secondary care nephrology clinics, hospitalised patients with AKI not followed up in nephrology clinic, participants of other aspects of the study. Participatory workshop workstream: Organisational and professional organisations with interest in acute kidney injury, professional networks, public and patient involvement and engagement groups

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Observational study workstream * Age 18-85 years * AKI stage 2 or 3 during hospital admission OR AKI stage 1 of at least 7 days duration during hospital admission * 60-90 days after peak creatinine Qualitative interview workstream * Age 18-85 years * AKI during hospital admission * 60-90 days after peak creatinine Participatory workshop workstream * Age 18-85 years * Relevant experience (as assessed by the investigator) which could include personal experience of an episode of hospitalised AKI as a patient of carer, experience of managing AKI or related problems in a professional capacity or knowledge of a particular community. Exclusion Criteria: Observational study workstream * Inability to give informed consent * No baseline creatinine available in previous 12 months * Pregnancy or breastfeeding * Current treatment with dialysis * Renal transplant * Pacemaker in situ * Previous amputation * Allergy to Omnipaque contrast agent (WP1 only) * Manifest thyrotoxicosis (WP1 only) * Ascites or significant (grade 3 to 4) peripheral oedema, defined as ≥6 mm pit, lasting for \>1 minute after 5-second compression over tibia or medial malleolus (WP1 only) Qualitative interview workstream * Inability to give informed consent * No baseline creatinine available in previous 12 months * Current treatment with dialysis * Renal transplant * Receiving palliative care Participatory workshop workstream * Inability to give informed consent * Inability to communicate in English (the qualitative workshops will be held in English)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospitals of Derby and Burton NHS Foundation Trust

    RECRUITING

    Derby, Derbyshire, DE22 3DT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.